Angelini Ventures marks its first investment in the cardiovascular and gene therapy space – and first in Asia, further ...

Biotech was starting to show signs of recovery after years of investor pullback—until new tariffs and economic uncertainty ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it ...

Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), today announced the ...

AGC Biologics, your friendly CDMO expert, today announced a multiphase partnership with Novelty Nobility Inc., a clinical-stage biotech company based in South Korea. Novelty Nobility will leverage AGC ...

Matica Biotechnology, a specialized CDMO for cell and gene therapies, has partnered with the National Center for Therapeutics ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund ...

Shares of Recursion Pharmaceuticals fell after the company reported a first-quarter loss. Shares slid 13.4% to $4.94 during Monday's trading, and the stock is down 27% year to date.

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 05, 2025 ...